FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to production of fused proteins, which are conditionally active versions of interleukin 2 (IL-12), and can be used in medicine for treating a tumour. Disclosed is conditionally active IL-12, which contains a fused polypeptide, which includes an IL-12 polypeptide, an element for prolonging half-life and an IL-12 blocking fragment connected by linkers.
EFFECT: invention provides obtaining a conditionally active prodrug of IL-12, having an increased half-life, which delivers active IL-12 when cleaved by a protease, especially to the desired sites of activity, such as the tumour microenvironment.
25 cl, 21 dwg, 3 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
ACTIVATED POLYPEPTIDES OF INTERLEUKIN-2 AND METHODS OF USE THEREOF | 2019 |
|
RU2826454C2 |
FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
Authors
Dates
2024-09-05—Published
2019-05-14—Filed